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ABSTRACT 
More than 50% of all cancer patients receive radiation therapy. The clinical delivery of curative 
radiation dose is strictly restricted by the proximal healthy tissues. We propose a dual-targeting 
strategy using vessel-targeted-radiosensitizing gold nanoparticles and conformal-image guided 
radiation therapy to specifically amplify damage in the tumor neoendothelium. The resulting 
tumor vascular disruption substantially improved the therapeutic outcome and subsidized the 
radiation/ nanoparticle toxicity, extending its utility to intransigent or non-resectable tumors that 
barely respond to standard therapies.   
KEYWORDS: Gold Nanoparticles; Image-Guided Radiation Therapy; Endothelial Radiation 
Damage; Tumor Vascular Disruption 
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Nanoparticles for radiation therapy have been an active area of research for several decades in 
oncology. More than 50% of cancer patients receive therapeutic radiation at some stage of their 
treatment course. Although highly effective for inflicting cellular damage, the specificity of 
radiation therapy is mainly derived from the geometric restriction of radiation beams. Sparing of 
healthy tissues and organs from radiation can be particularly challenging when treating tumors 
that are located in deep-seated anatomical locations. A strategy to intensify the tumor damage 
without adding additional risk to the healthy tissue is extremely advantageous in the clinic. 
 
Multifunctional metallic nanoparticles have excellent potential as radiosensitizing agents 
primarily due to the superior interaction cross-section for high-z-elements when irradiated with 
low-energy x-rays
1
. This interaction results in the emission of short-range photoelectrons and 
Auger electrons which can impose damage to the tumor cellular or sub-cellular structures
2, 3
. 
Gold nanoparticles (AuNP) are of interest in radiation therapy due to its high k-edge (≈81 keV) 
and biocompatibility. In contrast to i.v. administered radioactive probes, gold is non-toxic in 
moderate quantities
4-6
. By specifically targeting AuNP to malignant tumor cells using ‘enhanced 
permeability and retention’ (EPR)- driven passive or peptide-/ antibody- mediated active tumor 
targeting, radiation damage can be invoked to the tumor cells upon irradiation
7-16
. Several 
preclinical studies have demonstrated this in different preclinical tumors, including prostate, 
breast, head and neck, cervical, sarcoma, glioblastoma, colorectal and melanoma
14, 17-25
. 
 
Previous studies have examined the potential for a classic clonogenic effect in cancer cells 
leading to improved radiotherapeutic efficacy. To this end, EPR-mediated passive targeting has 
been used to attain high AuNP deposition in the tumor cells. Although there are several benefits 
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attributed to passive tumor targeting, recent preclinical and clinical studies have shown that 
EPR-mediated passive tumor targeting was significantly less efficient (≈2-fold) in slow-growing 
animal pancreatic adenocarcinoma (PDAC) models versus fast-growing models
26-32
. This is 
primarily due to the fact that slow-growing tumors possess more mature and intact tumor blood 
vessels, amply sheathed by α-SMA and pericytes, leading to less vascular leakiness compared to 
the rapidly growing (aggressive) tumors which host leaky immature vessels
30, 33
. EPR is highly 
variable not only among different tumors, but also within the same tumor type, and often within 
different sub-regions of a single tumor
27, 28, 34
.  
 
Another critical factor that hampers drug/ nanoparticle delivery to the tumor cells is the highly 
heterogeneous and dense fibrotic microenvironment of solid tumor (especially in PDAC tumor). 
It is therefore extremely difficult for anticancer drugs (for ex. Gemcitabine), proteins, peptides 
or antibodies to diffuse and penetrate through the tumor interstitium to reach the cancer cells
29, 
35
. In principle, this inherent tumor pathophysiology which regulates the poor diffusion of 
nanoparticles (beyond tumor vasculature and its periphery) is a serious limitation for cellular 
AuNP-mediated radiation therapy
35
.  
 
Tumor neovasculature is an important target for both chemo- and radiation- therapy
36-39
. 
Studies show that even clonogenic cellular dysfunction due to radiation is primarily mediated 
by the microvascular endothelial damage
36, 40-42
. To this end, chemical vascular disrupting 
agents have been shown to be effective either alone or in combination with radiation therapy. 
However, recent clinical trials showed severe off-target toxicity issues associated with chemical 
vascular disrupting agent therapies
41-44
. On the other hand, targeted-AuNP can minimize off-
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target localization, and improve the overall localization at the tumor endothelium. In addition to 
this, the mm-scale accuracy of modern clinical image-guided radiation therapy can largely avoid 
AuNP activation in other healthy organs. This “two-fold targeting strategy” will minimize the 
normal tissue toxicity and consequently improve the therapeutic efficacy considerably
24, 45-47
. 
 
 We have proposed a dual-targeting strategy by specific targeting of the tumor blood 
vasculature with targeted-gold nanoparticles and image-guided irradiation to improve radiation 
outcome by inducing vascular damage. Using Monte Carlo simulations, empirical electron 
range data and analytical calculations, our previous studies clearly show that gold nanoparticles 
will contribute to substantial dose enhancement to the tumor endothelial cells even without a 
specific cellular uptake
45
. In the following study, we experimentally validated the hypothesis 
that tumor-specific vascular disruption could be mediated by the administration of targeted gold 
nanoparticle followed by targeted irradiation in pancreatic tumor model. In our experimental 
design, gold nanoparticles were co-functionalized with a targeting- and imaging- ligand and 
injected into mice-bearing (Panc-1) pancreatic tumor xenografts (≈1.2 mg/g of Au i.v.). The 
tumor was then irradiated (10 Gy) and the vessel-damage response was assessed using a series 
of different analytical / imaging techniques in vitro and in vivo. The schematic depiction 
illustrates some of the prototypical responses of vessel rupture post-irradiation using gold 
nanoparticles, as further demonstrated in this study (Figure 1A-B).  
 
PEGylated gold nanoparticles (AuNP) were prepared and co-functionalized with Arg-Gly-Asp 
(-RGD), a tumor neovascular targeting ligand and a near infrared dye, AF647. The bi-functional 
gold nanoparticle was prepared using a standard two-step process as described in the Materials 
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and Methods section. The THPC-stabilized nanoparticle were further functionalized to impart 
carboxylic (-COOH) and amino (-NH2) pendant groups which further undergoes EDC coupling 
reaction to covalently attach -RGD and AF-647 moieties, the targeting and the imaging agents 
(Figure 2A). Besides the high k-edge, the relative ease of AuNP multi-functionalization, and its 
superior stability vis-a-vis for ex. micelles, liposomes, lipid nanoparticles, antibody-conjugates 
etc., extends its utility in radiation therapy. PEG-functionalization, by virtue of its higher 
hydrophilicity and stearic hindrance abilities, reduces the opsonization and improves the overall 
circulation kinetics and tumor accumulation. A near infrared dye-AF647 was chemically tagged 
to the AuNP to facilitate fluorescence/ confocal imaging. RGD (Arg-Gly-Asp), an oligopeptide, 
has high affinity for the transmembrane heterodimer αvβ3 integrin receptors which are highly 
over-expressed on the activated tumor neoendothelium. Since its inception in the 1980’s, it has 
been used as a standard tumor vascular targeting ligand
28, 48, 49
. For the remainder of this study, 
the neovascular-targeted (-RGD), PEGylated and fluorophore-tagged AuNP formulation will be 
referred to as RGD:AuNP. With a spherical morphology, the core size of the RGD:AuNP was 
found to be ≈ 2-3 nm (by TEM imaging), and a hydrodynamic size of ≈ 8-10 nm was measured 
by DLS (Figure 2B-C). Size plays a determinant role in predicting the radiotherapeutic benefits. 
Several studies have demonstrated that AuNP with the size of ≈ 10-12 nm can produce a high 
radiosensitization effect
50
. The avg. zeta potential (surface charge) was -11.07 ± 1.07 in PBS 
(7.4). Absorption and fluorescence spectra of RGD:AuNP showed the integrity of AF-647 post-
labeling by listing distinct peaks at the anticipated absorption/ fluorescence λmax of 650/ 668 nm 
(Figure 2D). 
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For optimal therapeutic response, favorable in vivo accumulation and tumor blood vessel 
localization of nanoparticles in the tumor is crucial. To investigate the AuNP distribution profile 
in Panc-1- tumor bearing mice, we performed a series of high-resolution imaging techniques at 
early (1 h, post-i.v.) and late (24 h, post-i.v.) time points after RGD:AuNP administration. When 
STEM (Scanning transmission electron microscopy) imaging and TEM (Transmission electron 
microscopy) imaging assessed the early (1 h-p.i.) uptake kinetics of RGD-AuNP, LIBS (Laser-
induced breakdown spectroscopy), fluorescence/ bright-field imaging and ICPMS (Inductively 
coupled plasma mass spectrometry) studies were used to trace the late localization (24 h-p.i.) of 
RGD-AuNP. Early distribution of AuNP in the tumor endothelium was detected as bright 
contrast signals in the STEM-EDX imaging (Figure 3A-B). Distinct Au peaks simultaneously 
corroborating with the bright signals (inset) were obtained using the EDX spectral read-outs. 
Furthermore, in a functional tumor blood vessel, large clusters of nanoparticles were actively 
taken up by the tumor endothelial cells as observed using TEM imaging (Figure 3C-E). In line 
with the previous reports, the uptake of RGD:AuNP may be primarily mediated by the active 
clathrin/caveolae- mediated endocytosis
51-54
. However, using non-targeted gold nanoparticles, 
no active endothelial uptake was observed (Figure S1). At 24 h post-i.v. injection, localization 
of RGD:AuNP was visualized close to the tumor blood vessels (Figure 3F-H). LIBS imaging, a 
novel advanced technique to specifically detect heavy metals/ elements showed heterogeneous 
distribution of gold (RGD:AuNP) in the tumor tissue
55, 56
. The spectral read-outs resonated with 
corresponding peaks for gold in the treated-samples vs. non-treated samples (Figure 3I-L). More 
to it, the (bio) distribution of RGD:AuNP in the tumor and other vital organs were measured 
with IC-PMS at 24 h-post-i.v.. Preferentially high accumulation in the tumor was apparently 
observed (Figure 3M). Other reported studies have shown that ≈10 nm-sized gold nanoparticles 
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that accumulate in the liver (kupffer cells) are eventually cleared by the hepato-biliary 
pathways
57
. In addition to this, the collimated radiation set-up that we employed largely reduces 
RGD:AuNP activation in off-target organs such as the liver. This has been confirmed by 
assessing the radiation dose distribution in tumor and other organs (which is explained in the 
upcoming sections). Due to the presence of over-expressed integrin receptors in the activated 
tumor endothelium of PDAC tumors, strong co-localization between RGD:AuNP and tumor 
blood vessels was observed in vivo at 24 h-p.i. using fluorescence imaging (Figure 3N). 
 
In the following in vitro and in vivo results, the group receiving both RGD:AuNP and 
irradiation is referred to as +RGD:AuNP/+IR, the group receiving RGD:AuNP alone is referred 
to as +RGD:AuNP/–IR, the group receiving irradiation alone is referred to as –RGD:AuNP/+IR, 
and the group receiving neither AuNP nor irradiation is –RGD:AuNP/–IR. To validate the 
hypothesis of endothelial damage using RGD:AuNP upon irradiation, we performed an in vitro 
study using human umbilical vein endothelial cells (HUVEC) over-expressing the αvβ3 integrins 
during proliferation. By using a set of treated and non-treated controls (+RGD:AuNP/+IR, 
+RGD:AuNP/–IR, –RGD:AuNP/+IR and –RGD:AuNP/–IR), three different radiation doses (10 
Gy, 5 Gy, and 0 Gy) were tested in vitro. Results obtained from the crystal violet assay 
displayed obvious qualitative differences between the treated (10 Gy, 5 Gy) and the non-treated 
(0 Gy) samples (Figure 4A). Unlike colony forming tumor cells, endothelial cells formed a 
single monolayer in the plates. The cells were therefore lysed to extract the stain from viable 
cells and the absorbance was measured at 590 nm. A statistically significant difference (P<0.05) 
in the HUVEC survival was observed for the +RGD:AuNP/+IR (10 Gy) sampled vs. the un-
irradiated controls (58% vs. 98%) (Figure 4B). In addition, the sensitivity enhancement ratios 
  
 9 
(SER, defined as the ratio of survival fractions after irradiation with and without nanoparticles) 
were calculated at 10 Gy and 5 Gy, and was found to be 1.2 ± .022 and 1.0 ± 0.028, 
respectively. Furthermore, on assessing the morphological changes in the HUVEC cells post-IR 
using phase contrast microscopy, increased endothelial cell rupture was observed for the 
radiation-treated ones (+RGD:AuNP/+IR) compared to non-treated samples (+RGD:AuNP/–IR 
and –RGD:AuNP/–IR) samples (Figure 4C), demonstrating the effect of the radiation. Nearly 
two-fold differences (33% vs. 41% vs. 95%) in the cell survival were observed between the 
RGD:AuNP treated/ irradiated group vs. non-treated group (Figure 4D). Furthermore, the 
uptake of nanoparticles (RGD-AuNP) was also compared with the respective survival in these 
in vitro endothelial models (see supplementary Figure S2). 
 
Clinical radiation therapy of pancreatic cancer is often limited by the close proximity of 
organs-at-risk such as liver, duodenum, spleen and kidneys. In our study, we used a Small 
Animal Radiation Research Platform (SARRP) to perform image-guided radiation studies 
(Xtrahl, Inc.). By applying collimated radiation beams from two orthogonal angles, optimal 
tumor coverage was achieved and the exposure to other organs was grossly minimized (Figure 
5A). To corroborate this, we performed image-guided dosimetry studies (Muriplan V.1.3.0) to 
determine the dose distribution in the tumor and normal tissues (Figure 5B). The results clearly 
indicate that >80% of the tumor region received a radiation dose of at least 10 Gy while the 
normal tissues were largely spared (<5%) (Figure 5C-D). Further histological staining of the 
adjacent muscle tissue showed no apparent radiation damage (see supplementary Figure S3). 
This set-up ensures maximum dose at the tumors with minimal effect on other healthy tissues / 
organs.  
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We further evaluated the potential of RGD:AuNP to induce tumor vascular damage in Panc-1 
tumor xenografts at 24 h post-IR. 3D-confocal imaging was performed on excised tumor tissue 
pre-injected with a standard vessel marker, FITC-dextran (70 kDa; 60 µL of 1 mg/ml). For the 
+RGD:AuNP/+IR cohort, a high degree of specific vascular damage was observed compared to 
the respective controls (Figure 6A-D). The tumor endothelial cells were severely damaged by 
the +RGD:AuNP/+IR combined treatment. However in the respective controls, intact blood 
vessels with consistent endothelial integrity / functionality and uniformity were noticed (Figure 
6B-D). Of note, two different types of vascular damage were apparently visible: fragmented 
vessels and diffused vessels (see supplementary Figure S4). Bright-field imaging was further 
employed to assess the morphological damage at the single vessel scale. Complete rupture of 
tumor vascular endothelium and damage to the vessel was clearly evident further confirming the 
previous results (Figure 6A). Partially segregated endothelial cells were present in the vicinity 
of damage site (cf. arrowheads). Essentially, the control batch showed normal tumor vascularity 
and endothelial integrity without any rupture (Figure 6F-H). We performed CD34 stainings to 
specifically detect the damage at the tumor microvasculature. To this end, large depletion of 
vessel structure and integrity was seen in the +RGD:AuNP/+IR samples compared to the 
respective controls (Figure 6I-L). At higher magnifications (2500x), TEM imaging clearly 
showed unambiguous damage to the tumor endothelium and the disruption of tumor blood 
vessel (Figure 6M). In the controls, however, endothelial cells were intact and sufficiently 
protected by the basement membrane (BM) and pericytes (Figure 6N-P). All of these 
observations using diverse techniques to evaluate different aspects of damage clearly show that 
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the targeted nanoparticles induced specific, catastrophic vascular damage in pancreatic tumors 
following irradiation. 
 
In order to assess the direct radiation damage response at the molecular level, we measured 
overall tumor suppression and specific DNA damage (double-strand breaks) using H&E and -
H2AX staining. Considerable reduction in the tumor proliferation and massive cell death was 
observed for the +RGD:AuNP/+IR samples compared to the respective controls (Figure 7A-D). 
Assuming the effect to be a more generic tumor suppression response, we further investigated 
the possibilities for specific radiation damage. The effect of irradiation on the tumor and tumor 
endothelial cells at the DNA level was measured by using -H2AX staining, taking into account 
recent experimental evidence of the temporal variations of -H2AX positive foci formation in 
tumor tissue post-IR
58
. We irradiated tumors +/- RGD:AuNP and dissected the tumors 30-40 
minutes post-IR. -H2AX foci-formation in the tumor specimens showed a high degree of DNA 
double-strand breaks in the +RGD:AuNP/+IR samples (Figure 7E) compared to the controls 
(Figure 7F-H). Additionally, a large effect on the tumor endothelial cells was also observed 
(Figure 7I-J). Quantification of the DNA double strand breaks by H2AX staining showed ≈ 3-
fold increase (P<0.001) in the radiation specific DNA damage in the ‘nanoparticle-radiation’ 
group (+RGD:AuNP/+IR: 57%) compared to the ‘radiation only’ group (–RGD:AuNP/+IR: 
19%), and almost ≈ 10-fold difference (P<0.001) compared to other controls (+RGD:AuNP/–
IRR: 6% and –RGD:AuNP/–IR: 6%) (Figure 7K). 
 
Our experimental findings support the original concept of targeted gold nanoparticles to 
induce specific tumor vascular damage during radiation therapy. Unlike cellular targeting, 
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which is often severely restricted by tissue (and physical) barriers, activated tumor endothelial 
targeting enables direct systemic access of nanoparticles to the over-expressed vascular 
targeting motifs. Moreover, shutting off a tumor blood capillary can affect numerous 
proliferating cancer cells, and an anti-tumorigenic (or anti-angiogenic) effect can be indirectly 
potentiated. By means of inducing both direct and indirect tumor cell killing mechanisms, we 
anticipate that this innovative treatment modality has promising clinical potential. Clinically 
administered chemical vascular disrupting agents have suffered from serious toxicity concerns. 
Combrestatin, a clinical vascular disrupting agent, showed fatal dose-limiting side effects 
including pulmonary embolism and coronary vasospasm when tested in human trials. In our 
approach, however, the activating radiation beams can be exclusively restricted to the tumor 
(containing actively-targeted gold nanoparticles). This dual-targeting platform could help 
maximize the therapeutic index by 1) increasing tumor damage and/or 2) reducing the amount 
of radiation dose needed to provide the same therapy effect and therefore limiting collateral 
damage to healthy tissues. The gold nanoparticles which are localized at other parts of the body 
(largely unaffected by radiation) will eventually be cleared by several phase degradation/ 
detoxification mechanisms
59
. The further impact of nanoparticle-mediated vascular damage 
using radiation therapy in terms of halting tumor blood vessel functionality and its downstream 
effects are currently under investigation. Therapy-induced hypoxia may be a challenge to a 
fractionated clinical approach, but this needs to be independently investigated. To summarize, 
this dual-targeting strategy holds great translational potential in radiation oncology. Application 
of this concept to other intransigent or non-resectable tumor types for which radiation delivery 
is limited by adjacent organs adds to the potential clinical impact. The data presented in this 
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paper represents the first in-depth experimental investigation of tumor vascular disruption with 
metallic nanoparticles, a novel strategy in radiation therapy.  
 
ASSOCIATED CONTENT 
Supporting Information  
Materials and methods to characterize different polymeric nanomedicines are elaborated in the 
supplementary information’s. This material is available free of charge via the Internet at 
http://pubs.acs.org.  
AUTHOR INFORMATION 
Corresponding Authors 
*Tel.: +1-214-250-0923. Email: sijumon@gmail.com; skunjachan@lroc.harvard.edu 
*Tel.: +1-617-525-7136. Email: rberbeco@lroc.harvard.edu  
 
Notes 
The authors declare no competing financial interest 
 
ACKNOWLEDGMENTS 
We acknowledge the efforts by Dr. Houari Korideck for assistance with the SARRP irradiations 
at Dana-Farber Cancer Institute, and the histology core facility at Brigham and Women’s 
Hospital and Harvard Medical School, and the TEM imaging core facility at Harvard Medical 
School. This project was supported, in part, by a grant from the JCRT Foundation and by award 
numbers R03 CA164645 and R21 CA188833 from the National Cancer Institute (NCI). The 
  
 14 
content of this manuscript is solely the responsibility of the authors and does not necessarily 
represent the official views of the NCI or NIH.  
  
 15 
Figures 
 
 
 
 
Figure 1. Experimental design and concept. (A) Schematic illustration of a tumor angiogenic blood 
vessel which, after active (vascular) targeting by gold nanoparticles to the αvβ3 integrin receptors and 
subsequent irradiation, suffers tumor endothelial disruption. The cross-sectional view depicts some of 
the prototypical responses related to ‘vascular disruption’ where the endothelium (E), pericytes (P), 
basement membrane (BM) and endothelial nuclei (N) undergo morphological changes and membrane 
destabilization leading to vessel rupture. (B) Roughly 25 days after s.c. tumor inoculation in NCr nude 
mice, ≈ 5-8 mm2 sized Panc-1 tumor xenografts were obtained. The gold nanoparticles (referred to as 
RGD:AuNP) were synthesized and functionalized with the targeting ligand (RGD) and the imaging agent 
(AF-647). After proper characterization, RGD:AuNP (1.25 mg/ml equiv. Au in 200 µL) was 
administered into tumor-bearing mice and irradiated at 24 h post-i.v. injection. FITC-dextran (70 kDa; 1 
mg/ml) was injected at 24 h after the irradiation and the mouse was sacrificed in 5-10 min to excise the 
tumor and other vital organs for further investigations. 
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Figure 2. Chemical synthesis and characterization of functionalized gold nanoparticles for 
vascular tumor targeting. (A) Schematic representation of step-wise synthesis where PEGylated gold 
nanoparticles (AuNP) were bi-functionalized with Arg-Gly-Asp (RGD) and a near infrared imaging 
agent (AF647). The resultant product, PEG-RGD-AuNP-AF647 (or RGD:AuNP) was further purified 
and characterized. (B) RGD:AuNP showed spherical surface morphology (cf. inset) when analyzed 
using TEM imaging. (C) The particle size (core and hydrodynamic size) was measured by both TEM and 
DLS, and its core size was estimated to be ≈ 2-3 nm, whereas the hydrodynamic size was ≈ 8-10 nm. (D) 
The absorption and fluorescence spectra of RGD:AuNP was recorded post-labeling and it was found to 
be λmax of 650/ 668 nm, in agreement with previous reported studies.  
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Figure 3. RGD:AuNP localization in vivo and tumor vascular targeting. (A-B) STEM (Scanning 
transmission electron microscopy) imaging detects the presence of targeted nanoparticles (indicated by 
bright contrast) on the tumor vessels at 1 h after RGD-AuNP injection in Panc-1 tumor bearing mice. 
The corresponding EDX spectral read-outs show distinct peaks which are specific for Au (see insets) in 
the samples. Apparently no gold was seen in the respective controls. (C-E) TEM images show the early 
uptake (1 h) of nanoparticles by the tumor endothelial cells in vivo. Higher magnified images (manual) 
indicate clathrin/ caveolae- mediated uptake at early/ late endosomal stages. E: Endothelium; N: 
Nucleus. (F-H) Bright field images show the RGD:AuNP localization close to the vessels at 1 h post-
administration. Higher manual magnification of those images show the formation of AuNP aggregates 
close to the tumor endothelium. (I-L) Laser induced breakdown spectroscopy (LIBS) imaging was 
carried out to specifically confirm the presence of RGD:AuNP localization within the tumor 24 h post-
i.v. Unlike TEM imaging, LIBS facilitates real-time monitoring of Au distribution within the tumors and 
directly correlates with the respective wavelengths in the corresponding spectral read-outs. (M) 
Biodistribution of RGD:AuNP in other organs was measured 24 h post-i.v. by ICPMS (n=3), and the 
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amount of Au was quantified based on the corresponding organ weight. The values represent average ± 
SD. (N) The co-localization of RGD:AuNP with FITC-dextran-labeled tumor endothelium was analyzed 
using fluorescence imaging. Strong co-localization is observed with (AF647-coupled) nanoparticle near 
the endothelial cells.  
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Figure 4.  In vitro radiation enhancement study. Human umbilical vein endothelial cells were treated 
(+/–) RGD:AuNP (indicated by * and # respectively) and exposed to three different radiation doses: 0 
Gy, 5 Gy and 10 Gy. All four treatment conditions were replicated in this study: +RGD:AuNP/+IR, 
+RGD:AuNP/–IR, –RGD:AuNP/+IR and –RGD:AuNP/–IR. (A-B) Crystal violet assay was performed 
on endothelial cells 1-week post-irradiation to detect the differences in the cell survival. The cells were 
lysed to extract and quantify crystal violet, by measuring its absorbance using a spectrophotometer at 
590 nm. The values represent Mean ± SD, and all the data was normalized to its respective non-treated 
controls. ** P < 0.05. (C-D) Phase contrast microscopy was performed 1-week post-IR to visualize the 
proliferation (or survival) of the endothelial cells. Apparently, clear differences in the cell density was 
observed between the treated vs. non-treated group. Bar:10x. Further quantification of the phase contrast 
microscopic images was carried out by counting the viable cells/ frame (using ImageJ) in RGD:AuNP 
treated vs. non-treated in both irradiated and non-irradiated controls. In total, n=30 representative 
images/ condition were analyzed. The values represent Mean ± SD, and all the data was normalized to its 
respective non-treated controls. **** P < 0.0005. 
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Figure 5. Small animal radiation research platform and radiation dose distribution in vivo. (A) 
Radiation set-up where each Panc-1 tumor xenograft was irradiated with 10 Gy (220 kVp) radiation 
beam. We used orthogonal, collimated beams in order to maximize the radiation dose exposure to the 
tumors and minimize the effect on (off-target) healthy tissues. (B) The representative coronal CT image 
shows the real-time distribution of radiation dose in the tumor and the surrounding tissue for 
RGD:AuNP-treated mouse with Panc-1 tumors. The isodose distribution shows high dose (95%-100%) 
in the tumor compared to the surrounding tissue. (C) Transverse (axial) section shows the isodose 
distribution specifically in the tumor. (D) The quantification of radiation doses from the cone beam CT 
images shows that more than 80% of the tumor received 10 Gy compared to the whole body.  
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Figure 6. Imaging tumor vascular disruption. (A-D) Confocal imaging with RGD:AuNP (red) and 
FITC-Dextran (green) shows a high degree of vascular damage at the indicated locations (white arrows) 
and the presence of highly dense RGD:AuNPs in its close proximity, compared to the respective 
controls. (E-H) Bright field imaging shows damaged endothelial cells, and a change in the morphology 
of red blood cells clearly demonstrates loss of functionality for some of these vessels.. The control 
samples showed intact vessels and prominent endothelium. (I-L) CD34 IHC shows collapsed vessels and 
altered morphology (red marker) compared to the respective controls. (M-P) TEM imaging clearly 
confirms the endothelial rupture (see arrows). In the +RGD:AuNP/+IR samples, endothelial cells were 
detached and the cell nuclei damaged. The control samples showed high integrity and intact morphology. 
EN: Endothelial nucleus; RBC: Red blood cells; BM: Basement membrane.   
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Figure 7. Assessing radiation outcome and specific DNA damage. (A-D) The H&E staining revealed 
the effect of radiation on the Panc-1 tumor xenograft. Massive cell death was observed in the 
RGD:AuNP treated samples compared to respective controls. (E-H) By -H2AX staining, we measured 
radiation induced DNA double strand breaks in the tumor. Color. Dark-brown: -H2AX-positive nuclei; 
Blue: Hematoxylin-positive nuclei (I-J) This effect was remarkable in the tumor blood vessels especially 
in the endothelial cell nucleus (denoted by ‘E’) showing high degree of radiation damage. (K) 
Quantification of the -H2AX signals showed significant increase (≈3-fold) in the magnitude of damage 
for the +RGD:AuNP/+IR samples compared to the controls (n= 60/cohort). The values represent average 
± SD. **** P < 0.0005. 
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